BioSpace News Archive

Fact.MR, A Market Research And Competitive Intelligence Provider – The global Psychotic Disorder Treatment market is bound to be valued US$ 13.6 Bn in 2022 and have a CAGR of 6.1% between 2022 and 2032.

Oramed Pharmaceuticals Inc. announced today that it has enrolled and randomized over 50% of the planned 450 patients for its international multicenter Phase 3 ORA-D-013-2 trial of its oral insulin capsule, ORMD-0801, for the treatment of type 2 diabetes (T2D).

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), announced today the start of a preclinical collaboration with the CMT Research Foundation (CMTRF), a U.S.-based patient-led, non-profit organization focused on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease, to explore Oryzon’s histone deacetylase 6 (HDAC6) inhibitors.

Virax Biolabs Group Limited (“Virax” or the “Company”) (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, today launched distribution of Monkeypox and Varicella-Zoster Viruses Real Time PCR Detection Kits in response to the world’s major Monkeypox outbreak

PDS Biotechnology Corporation today announced that the Company will release financial results for the second quarter of 2022 on Monday, August 8, 2022, before the market opens.

ProPhase Labs, Inc. (NASDAQ: PRPH), a rapidly growing and diversified diagnostics, genomics and biotech company, today announced that its Board of Directors has authorized a stock repurchase program of up to $6 million in ProPhase Labs’ common stock.

Moleculera Labs, Inc. (Moleculera) and General Genomics, Inc. (GGI) announce the formation of a strategic alliance between the two companies.

Advanced Instruments announced today at the American Association for Clinical Chemistry trade show in Chicago the newest addition to its clinical line of freezing point osmometers, the OsmoPRO MAX Automated Osmometer.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30, 2022 on Thursday, August 4, 2022.

Today IMV, part of Science and Medicine Group, the leading market research and business intelligence provider to the laboratory diagnostic industry, announced the first wave of category winners of the 2022 IMV ServiceTrak™ Clinical Laboratory Awards.